Interferon News and Research

RSS

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

3 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

German researchers have found a significant association of IL28B genotypes to interferon-based antiviral treatment outcome, and to graft inflammation caused by hepatitis C virus (HCV). The study determined that the presence of G-allele serves as a marker for severe HCV-induced graft inflammation, as well as a predictor for unsuccessful treatment. Study findings—the largest to report on the role IL28B variants in a transplant cohort with recurrent HCV—are published in the March issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

2 Mar 2011

Cancer drug may help combat flu

Ever get a flu shot and still get the flu? If so, there's new hope for flu-free winters in the years to come thanks to a new discovery by researchers who found that a drug called DMXAA, originally developed as anti-tumor agent, enhances the ability of flu vaccines to ward off this deadly virus.

1 Mar 2011

Scripps Health offers genetic testing to patients with Hepatitis C

Scripps Health is one of the first health systems in the United States to offer genetic testing as part of its care for hepatitis C patients planning to undergo drug treatment.

28 Feb 2011

New research: Reovirus infected melanoma cells secrete proteins that can kill cancer

Reoviruses are successfully being used in clinical trials to treat patients with cancer. Not only does the virus cause cancer cells to die, it also forces them to release pro-inflammatory chemokines and cytokines, which in turn causes the patient's immune system to attack the disease.

21 Feb 2011

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today that a profile of the company and its interferon payload technology platform and drug discovery pipeline is featured in the February 7 issue of BioCentury, one of the most widely read publications in the pharma and biotech industries.

14 Feb 2011

Idenix announces updates on HCV and HIV clinical development programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced updates to three clinical development programs.

10 Feb 2011

Immune protein exacerbates skin cancer due to sun exposure: Study

An unexpected immune protein exacerbates cancer due to sun exposure, report researchers in the January 27th issue of Nature. The study suggests that drugs blocking the protein might halt tumor growth in skin cancer patients.

3 Feb 2011

Positive results from Factor IX-CTP comparative study in hemophilic mice

PROLOR Biotech, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX in Factor IX-depleted hemophilic mice.

3 Feb 2011

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.

1 Feb 2011

Histamine can be an important molecule to develop new treatments for MS

If you think histamines are your nemesis during allergy season, here's something that might change your perspective. New research published in the Journal of Leukocyte Biology shows that histamine could be an important molecule to developing new treatments for multiple sclerosis.

1 Feb 2011

Interferon-alpha associated with increased risk of atherosclerosis in patients with SLE

Researchers in China have demonstrated interferon-alpha (IFN-α) is associated with increased risk of atherosclerosis in patients with systemic lupus erythematosus (SLE). For the first time, IFN-α priming was shown to promote lipid uptake and foam cell formation—a crucial step in plaque build-up. This activation of the IFN signaling pathway may be linked to the premature atherosclerosis risk in SLE.

27 Jan 2011

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.

27 Jan 2011

Anadys begins dosing in ANA598 Phase IIb study for hepatitis C

Anadys Pharmaceuticals, announced today that dosing has begun in the Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin in hepatitis C patients.

26 Jan 2011

Pill for multiple sclerosis in the pipeline

Multiple Sclerosis or MS is a severely disabling disease that affects 100,000 in the UK. Now a new pill has been developed to treat multiple sclerosis which means there would be no need for injections. European health experts - European Medicines Agency (EMA) have given the new drug Gilenya, the brand name for the drug fingolimod, approval which would grant it EU wide acceptance.

25 Jan 2011

Evaluating patients for genetic variations impacts adherence to antiviral therapy

In two recent studies, researchers have identified two functional variants in the inosine triphosphatase (ITPA) gene that protect patients with hepatitis C virus (HCV) against anemia brought on by antiviral treatment. The ability to identify those patients protected against treatment-induced anemia will ensure completion of antiviral therapy and successful elimination of the virus.

25 Jan 2011

ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis

ALLOZYNE, Inc. announced today, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties.

11 Jan 2011

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

Bristol-Myers Squibb Company and Pharmasset announced today that the companies have entered into a clinical collaboration agreement to evaluate the utility of BMS-790052, Bristol-Myers Squibb's NS5A replication complex inhibitor, in combination with PSI-7977, Pharmasset's nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus.

11 Jan 2011

Interferon News and Research

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Cancer drug may help combat flu

Scripps Health offers genetic testing to patients with Hepatitis C

New research: Reovirus infected melanoma cells secrete proteins that can kill cancer

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

Idenix announces updates on HCV and HIV clinical development programs

Immune protein exacerbates skin cancer due to sun exposure: Study

Positive results from Factor IX-CTP comparative study in hemophilic mice

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Histamine can be an important molecule to develop new treatments for MS

Interferon-alpha associated with increased risk of atherosclerosis in patients with SLE

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Anadys begins dosing in ANA598 Phase IIb study for hepatitis C

Pill for multiple sclerosis in the pipeline

Evaluating patients for genetic variations impacts adherence to antiviral therapy

ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News